Frontier Biotechnologies EBITDA

Mitä Frontier Biotechnologies tekee? Frontier Biotechnologies, Inc. develops and sells medicines through its product portfolio, including Aikening and the Combination regiment of Albuvirtide (ABT) + 3BNC117, which is in clinical stage for HIV treatment. The company also offers transdermal analgesic patch AB001 for muscle, skeleton, and joint pain, currently in clinical development. Frontier Biotechnologies operates within the China market and serves overseas markets with its pharmaceutical products. The company generates revenue primarily from the research, development, and sale of its clinical-stage medicines, targeting both domestic and international healthcare providers and distributors. Its products are positioned for treatment of HIV and pain management, with AB001 focusing on non-invasive pain relief solutions. Frontier Biotechnologies focuses on advancing its pipeline through clinical trials to bring these therapies to market. Frontier Biotechnologies, Inc. is a biotechnology firm headquartered in Nanjing, Jiangsu, with 495 full-time employees. It conducts its business activities in China and overseas, leveraging its R&D capabilities to develop innovative treatments for unmet medical needs. The firm's revenue streams are derived from the commercialization of its pipeline products once they reach the market. Frontier Biotechnologies on yksi Eurpooliin suosituimmista yhtiöistä.